Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia

Hagop M. Kantarjian, Moshe Talpaz, Susan O'Brien, Francis Giles, Guillermo Garcia-Manero, Stefan Faded, Deborah Thomas, Jianqin Shan, Mary Beth Rios, Jorge Cortes

Research output: Contribution to journalArticle

Abstract

We investigated whether increasing the dose of imatinib mesylate might overcome drug resistance in patients with Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) whose disease manifests relapse or refractoriness to therapy. Fifty-four patients with Ph+ CML in chronic phase and with hematologic or cytogenetic resistance or relapse on imatinib mesylate therapy at 400 mg orally daily were treated with a higher dose of 400 mg orally twice daily (800 mg daily, 47 patients; or 600 mg daily increased from 300 mg daily, 7 patients). Among 20 patients treated for hematologic resistance or relapse, 13 (65%) achieved a complete (n = 9) or partial (n = 4) hematologic response, but only 1 had a cytogenetic partial response (Ph reduction from 100% to 10%) and 1 had a minor response (Ph reduction from 100% to 50%). Among 34 patients treated for cytogenetic resistance or relapse, 19 (56%) achieved a complete (n = 6) or partial (n = 7) cytogenetic response. We conclude that higher doses of imatinib mesylate may overcome disease-poor response to conventional doses and that this approach deserves further evaluation as frontline therapy for newly diagnosed CML.

Original languageEnglish (US)
Pages (from-to)473-475
Number of pages3
JournalBlood
Volume101
Issue number2
DOIs
StatePublished - Jan 15 2003
Externally publishedYes

Fingerprint

Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Cytogenetics
Recurrence
Chromosomes
Therapeutics
Leukemia, Myeloid, Chronic Phase
Philadelphia Chromosome
Drug Resistance
Pharmaceutical Preparations
Imatinib Mesylate

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Cite this

Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia. / Kantarjian, Hagop M.; Talpaz, Moshe; O'Brien, Susan; Giles, Francis; Garcia-Manero, Guillermo; Faded, Stefan; Thomas, Deborah; Shan, Jianqin; Rios, Mary Beth; Cortes, Jorge.

In: Blood, Vol. 101, No. 2, 15.01.2003, p. 473-475.

Research output: Contribution to journalArticle

Kantarjian, HM, Talpaz, M, O'Brien, S, Giles, F, Garcia-Manero, G, Faded, S, Thomas, D, Shan, J, Rios, MB & Cortes, J 2003, 'Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia', Blood, vol. 101, no. 2, pp. 473-475. https://doi.org/10.1182/blood-2002-05-1451
Kantarjian, Hagop M. ; Talpaz, Moshe ; O'Brien, Susan ; Giles, Francis ; Garcia-Manero, Guillermo ; Faded, Stefan ; Thomas, Deborah ; Shan, Jianqin ; Rios, Mary Beth ; Cortes, Jorge. / Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia. In: Blood. 2003 ; Vol. 101, No. 2. pp. 473-475.
@article{d40a1070432a4e34a5390052e9de38f3,
title = "Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia",
abstract = "We investigated whether increasing the dose of imatinib mesylate might overcome drug resistance in patients with Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) whose disease manifests relapse or refractoriness to therapy. Fifty-four patients with Ph+ CML in chronic phase and with hematologic or cytogenetic resistance or relapse on imatinib mesylate therapy at 400 mg orally daily were treated with a higher dose of 400 mg orally twice daily (800 mg daily, 47 patients; or 600 mg daily increased from 300 mg daily, 7 patients). Among 20 patients treated for hematologic resistance or relapse, 13 (65{\%}) achieved a complete (n = 9) or partial (n = 4) hematologic response, but only 1 had a cytogenetic partial response (Ph reduction from 100{\%} to 10{\%}) and 1 had a minor response (Ph reduction from 100{\%} to 50{\%}). Among 34 patients treated for cytogenetic resistance or relapse, 19 (56{\%}) achieved a complete (n = 6) or partial (n = 7) cytogenetic response. We conclude that higher doses of imatinib mesylate may overcome disease-poor response to conventional doses and that this approach deserves further evaluation as frontline therapy for newly diagnosed CML.",
author = "Kantarjian, {Hagop M.} and Moshe Talpaz and Susan O'Brien and Francis Giles and Guillermo Garcia-Manero and Stefan Faded and Deborah Thomas and Jianqin Shan and Rios, {Mary Beth} and Jorge Cortes",
year = "2003",
month = "1",
day = "15",
doi = "10.1182/blood-2002-05-1451",
language = "English (US)",
volume = "101",
pages = "473--475",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "2",

}

TY - JOUR

T1 - Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia

AU - Kantarjian, Hagop M.

AU - Talpaz, Moshe

AU - O'Brien, Susan

AU - Giles, Francis

AU - Garcia-Manero, Guillermo

AU - Faded, Stefan

AU - Thomas, Deborah

AU - Shan, Jianqin

AU - Rios, Mary Beth

AU - Cortes, Jorge

PY - 2003/1/15

Y1 - 2003/1/15

N2 - We investigated whether increasing the dose of imatinib mesylate might overcome drug resistance in patients with Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) whose disease manifests relapse or refractoriness to therapy. Fifty-four patients with Ph+ CML in chronic phase and with hematologic or cytogenetic resistance or relapse on imatinib mesylate therapy at 400 mg orally daily were treated with a higher dose of 400 mg orally twice daily (800 mg daily, 47 patients; or 600 mg daily increased from 300 mg daily, 7 patients). Among 20 patients treated for hematologic resistance or relapse, 13 (65%) achieved a complete (n = 9) or partial (n = 4) hematologic response, but only 1 had a cytogenetic partial response (Ph reduction from 100% to 10%) and 1 had a minor response (Ph reduction from 100% to 50%). Among 34 patients treated for cytogenetic resistance or relapse, 19 (56%) achieved a complete (n = 6) or partial (n = 7) cytogenetic response. We conclude that higher doses of imatinib mesylate may overcome disease-poor response to conventional doses and that this approach deserves further evaluation as frontline therapy for newly diagnosed CML.

AB - We investigated whether increasing the dose of imatinib mesylate might overcome drug resistance in patients with Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) whose disease manifests relapse or refractoriness to therapy. Fifty-four patients with Ph+ CML in chronic phase and with hematologic or cytogenetic resistance or relapse on imatinib mesylate therapy at 400 mg orally daily were treated with a higher dose of 400 mg orally twice daily (800 mg daily, 47 patients; or 600 mg daily increased from 300 mg daily, 7 patients). Among 20 patients treated for hematologic resistance or relapse, 13 (65%) achieved a complete (n = 9) or partial (n = 4) hematologic response, but only 1 had a cytogenetic partial response (Ph reduction from 100% to 10%) and 1 had a minor response (Ph reduction from 100% to 50%). Among 34 patients treated for cytogenetic resistance or relapse, 19 (56%) achieved a complete (n = 6) or partial (n = 7) cytogenetic response. We conclude that higher doses of imatinib mesylate may overcome disease-poor response to conventional doses and that this approach deserves further evaluation as frontline therapy for newly diagnosed CML.

UR - http://www.scopus.com/inward/record.url?scp=0037438467&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037438467&partnerID=8YFLogxK

U2 - 10.1182/blood-2002-05-1451

DO - 10.1182/blood-2002-05-1451

M3 - Article

C2 - 12393385

AN - SCOPUS:0037438467

VL - 101

SP - 473

EP - 475

JO - Blood

JF - Blood

SN - 0006-4971

IS - 2

ER -